Our Vision:

In this week’s blog, IMF Chief Medical Officer Dr. Joseph Mikhael tackles the top takeaways from the recently concluded annual meetings of the International Myeloma Working Group (IMWG), the American Society of Clinical Oncology (ASCO), and the European Hematology Association (EHA). Dr. Mikhael breaks down and summarizes the top takeaways — ones that hold the greatest impact for patients with myeloma. Read the blog and find out more about the latest developments in myeloma research and treatments — taken from some of the biggest and most prominent annual meetings of myeloma experts this year.  READ THE BLOG.

For 35 years, the International Myeloma Foundation (IMF) has been the heartbeat of the myeloma community. Our history is filled with the stories of those touched by myeloma. We see you—not just as a patient—but as a son, as a daughter, a husband, a wife, a parent, or a grandparent.    

This GivingTuesday, we realize you have many causes to choose to support. We ask you to make a choice that matters to the myeloma community. No gift is too small. Give today up until December 2, 2025, to help us reach our goal of $100,000 funds raised for those living with myeloma and their loved ones. GIVE NOW.

The next Las Voces de Mieloma (Spanish/virtual) Support Group will take place on Tuesday, November 18, from 10 a.m. - 11 a.m. PST. The Guest Speaker for this meeting will be Stefania Mancia, APRN,  a board-certified Nurse Practitioner specializing in malignant hematology and cellular therapy. She leads the Survivorship Program at Moffitt Malignant Hematology and Cellular Therapy, Memorial Cancer Institute. Ms. Manca will discuss long-term care at this meeting. REGISTER HERE. 

La próxima reunión del Grupo de Apoyo Las Voces de Mieloma (en español y virtual) se llevará a cabo el martes 18 de noviembre, de 10:00 a 11:00 a. m. (hora del Pacífico). La oradora invitada será Stefania Mancia, APRN, enfermera practicante certificada especializada en hematología maligna y terapia celular. Dirige el Programa de Supervivencia en Hematología Maligna y Terapia Celular del Instituto Oncológico Moffitt Memorial. La Sra. Mancia hablará sobre los cuidados a largo plazo. REGÍSTRATE AQUÍ.

On November 6, 2025, according to an FDA press release, "the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) for adults with high-risk smoldering multiple myeloma (SMM)." READ THE PRESS RELEASE.

Join the IMF Virtual Myeloma Community Workshop on Monday, November 17, at 3:00 p.m. PST | 4:00 p.m. MT | 5:00 p.m. CT | 6:00 p.m. p.m. EST for expert debates on key issues in myeloma care. Hear from IMF Vice President of Patient Support Robin Tuohy and top myeloma specialists as they discuss topics like treating high-risk smoldering myeloma, using MRD to guide therapy, and CAR T-cell treatment at first relapse. The program concludes with a live panel Q&A where attendees can ask their questions directly to the experts. REGISTER NOW.

The International Myeloma Foundation (IMF) is excited to announce that an in-person Myeloma Community Workshop will take place on Saturday, November 15, 2025, at the Sheraton Raleigh (421 South Salisbury Street, Raleigh, NC 27601). Visit the following link to see which myeloma experts will present at this event: LEARN MORE.